Paper alert: Tau biology, biomarkers, and therapeutics

We are excited to share the culmination of critical discussions from the Fall 2024 Alzheimer's Association Research Roundtable. The Research Roundtable serves as a forum for scientists and industry leaders to address key areas in the field, including drug development, clinical trials, and emerging research frameworks. This particular Roundtable, organized by Bess Frost, Hartmuth Kolb, Christopher Weber and committee members from Eisai Co., Ltd., Johnson & Johnson, Eli Lilly and Company, Novartis, and Roche, was focused on tau-based diagnostics and therapeutics. Our article highlights:

- Integration of tau biomarkers into the 2024 Revised Diagnostic Criteria for Alzheimer's Disease

- Updates on amyloid/tau PET imaging and modeling of biomarker trajectories

- Modeling tau pathology in the laboratory

- Tau-targeting therapeutics (ASOs, immunotherapies, small molecules) and innovations in drug delivery

- Insights into the interplay between anti-amyloid and anti-tau therapies and the design of combination trials.

- International regulatory perspectives on drug approval pathways for Alzheimer's disease

Read the full paper to learn more about where we currently stand with tau-based diagnostics and treatment strategies for Alzheimer's disease.